DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.

Autor:	Lin, Shengchao1 (AUTHOR) shengchao.lin@dualitybiologics.com, Zhang, Yu1 (AUTHOR), Yao, Jun1 (AUTHOR), Yang, Junjie1 (AUTHOR), Qiu, Yang1 (AUTHOR), Zhu, Zhongyuan1 (AUTHOR), Hua, Haiqing1 (AUTHOR) haiqing.hua@dualitybiologics.com
Zdroj:	Journal of Translational Medicine. 8/14/2024, Vol. 22 Issue 1, p1-13. 13p.
Databáze:	Academic Search Ultimate
Externí odkaz: